PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Barbara Burtness, MD - Multimodal Head and Neck Cancer Care Meets the Immunotherapy Era: A Look at the Changing Nature of Multidisciplinary Collaboration and Integrated Treatment StrategiesMedia: Enduring Material
Go online to PeerView.com/QMH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this educational activity, based on a live event developed by PeerView and the Head and Neck Cancer Alliance and held at the 2020 Multidisciplinary Head and Neck Cancers Symposium, a panel of oncology and radiology professionals assess the latest evidence on immune checkpoint blockade as a part of a multipronged management approach to head and neck cancer (HNC). During this activity, the experts also explore several practical issues arising from the integration of immunotherapy into practice, including the selection of immunotherapy as upfront treatment, management of immune-related events, the use of immune-based multimodal therapy, and referral of patients with resectable or locally advanced disease for clinical trials. Upon completion of this activity, participants should be better able to: Cite updated evidence on immune checkpoint inhibitors in squamous cell carcinoma of the head and neck across treatment settings and patient populations, Select single-agent and immune-based combination regimens for the management of patients with recurrent/metastatic head and neck cancer, including as upfront treatment or after progression on platinum chemotherapy, Summarize the clinical potential of immunotherapy as part of multimodal care in the locally advanced or resectable head and neck cancer settings, including in the context of a clinical trial testing combinations of checkpoint inhibitors with surgery and/or radiation, Manage immune-related adverse events in patients with squamous cell carcinoma of the head and neck receiving immunotherapy as single agents or in combination with other treatment modalities.